U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C25H31NO
Molecular Weight 361.5197
Optical Activity ( + / - )
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUTACLAMOL

SMILES

[H][C@]12C[C@](O)(CCN1C[C@]3([H])C4=CC=CC=C4CCC5=CC=CC2=C35)C(C)(C)C

InChI

InChIKey=ZZJYIKPMDIWRSN-TZBSWOFLSA-N
InChI=1S/C25H31NO/c1-24(2,3)25(27)13-14-26-16-21-19-9-5-4-7-17(19)11-12-18-8-6-10-20(23(18)21)22(26)15-25/h4-10,21-22,27H,11-16H2,1-3H3/t21-,22-,25-/m1/s1

HIDE SMILES / InChI

Molecular Formula C25H31NO
Molecular Weight 361.5197
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Butaclamol is an antipsychotic drug, which was studied for the treatment of schizophrenia. This drug has never marketed and now is used in research, because of its action as a dopamine receptor-blocking agent. Butaclamol consists of the two forms: (-)-butaclamol, an inactive drug and (+)-butaclamol, a potent neuroleptic drug.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
[3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor.
1990 Nov
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
1991 Apr 18
Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation.
1993 Sep 15
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
1998 Aug 21
Patents

Sample Use Guides

In Vivo Use Guide
Maximum clinical response appeared to be at the 20-40 mg. dose level. Extrapyramidal signs occurred at all doses, but with greater severity at higher doses. Excessive daytime drowsiness occurred in all groups but with longer duration and greater intensity in the 20 mg. group.
Route of Administration: Intraperitoneal
In Vitro Use Guide
Curator's Comment: The effects of the two enantiomers of butaclamol and of several neuroleptics on the apomorphine-elicited inhibition of synaptosomal tyrosine hydroxylase activity was investigated. The (+) but not the (-) enantiomer of butaclamol reverses the apomorphine-elicited enzyme inhibition. (+) Butaclamol is more potent than the other tested neuroleptics.
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:10:28 UTC 2023
Edited
by admin
on Fri Dec 15 16:10:28 UTC 2023
Record UNII
A7A2802VNL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BUTACLAMOL
INN  
INN  
Official Name English
butaclamol [INN]
Common Name English
1H-BENZO(6,7)CYCLOHEPTA(1,2,3-DE)-PYRIDO(2,1-A)ISOQUINOLIN-3-OL, 3-(1,1-DIMETHYLETHYL)-2,3,4,4A,8,9,13B,14-OCTAHYDRO-, (3.ALPHA.,4A.ALPHA.,13B.BETA.)-(±)-
Common Name English
(±)-3.ALPHA.-TERT-BUTYL-2,3,4,4A.BETA.,8,9,13B.ALPHA.,14-OCTAHYDRO-1H-BENZO(6,7)-CYCLOHEPTA(1,2,3-DE)PYRIDO(2,1-A)ISOQUINOLIN-3-OL
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66883
Created by admin on Fri Dec 15 16:10:28 UTC 2023 , Edited by admin on Fri Dec 15 16:10:28 UTC 2023
Code System Code Type Description
WIKIPEDIA
Butaclamol
Created by admin on Fri Dec 15 16:10:28 UTC 2023 , Edited by admin on Fri Dec 15 16:10:28 UTC 2023
PRIMARY
SMS_ID
100000088474
Created by admin on Fri Dec 15 16:10:28 UTC 2023 , Edited by admin on Fri Dec 15 16:10:28 UTC 2023
PRIMARY
EPA CompTox
DTXSID5048429
Created by admin on Fri Dec 15 16:10:28 UTC 2023 , Edited by admin on Fri Dec 15 16:10:28 UTC 2023
PRIMARY
INN
3478
Created by admin on Fri Dec 15 16:10:28 UTC 2023 , Edited by admin on Fri Dec 15 16:10:28 UTC 2023
PRIMARY
NCI_THESAURUS
C81088
Created by admin on Fri Dec 15 16:10:28 UTC 2023 , Edited by admin on Fri Dec 15 16:10:28 UTC 2023
PRIMARY
EVMPD
SUB05995MIG
Created by admin on Fri Dec 15 16:10:28 UTC 2023 , Edited by admin on Fri Dec 15 16:10:28 UTC 2023
PRIMARY
MESH
D002069
Created by admin on Fri Dec 15 16:10:28 UTC 2023 , Edited by admin on Fri Dec 15 16:10:28 UTC 2023
PRIMARY
CAS
36504-93-5
Created by admin on Fri Dec 15 16:10:28 UTC 2023 , Edited by admin on Fri Dec 15 16:10:28 UTC 2023
PRIMARY
FDA UNII
A7A2802VNL
Created by admin on Fri Dec 15 16:10:28 UTC 2023 , Edited by admin on Fri Dec 15 16:10:28 UTC 2023
PRIMARY
CHEBI
73298
Created by admin on Fri Dec 15 16:10:28 UTC 2023 , Edited by admin on Fri Dec 15 16:10:28 UTC 2023
PRIMARY
PUBCHEM
37461
Created by admin on Fri Dec 15 16:10:28 UTC 2023 , Edited by admin on Fri Dec 15 16:10:28 UTC 2023
PRIMARY
ChEMBL
CHEMBL8514
Created by admin on Fri Dec 15 16:10:28 UTC 2023 , Edited by admin on Fri Dec 15 16:10:28 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Binding Assay
IC50
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY